Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan versus standard of care in EGFR-mutated advanced nonsquamous non-small cell lung cancer after progression on a third-generation EGFR TKI
MOH_2025-09-10_014334Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AbbVie Inc. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2025-09-10_014334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-10_014334.